Importantly and encouragingly, we observed a significant trend of increasing ULT use from 55.6% in Stage 1–2 to 77.4% in Stage 4–5, evidence that supports better recognition and treatment of gout in this high-risk population.
← all excerpts
Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
1
—
—